Supplemental Fig. S1. Effect of finerenone compared to placebo on the risk for the cardiovascular composite endpoint according to prior treatment with sodium-glucose co-transporter-2 (SGLT-2) inhibitors. M-H, Mantel-Haenszel; CI, confidence interval; FIDELIO-DKD, Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease; FIGARO-DKD, Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease.